Alpha Compute Corp · NASDAQ:ALP
Alpha Compute — Portage Biotech — Investor Presentation (September 2022)
25 slides from Alpha Compute's investor presentation, Sep 14, 2022
Slide 1: Corporate Presentation
Corporate Presentation 1 Nasdaq: PRTG September 2022
Slide 2: Legal Disclaimer
Legal Disclaimer 2 This presentation is for information purposes only . This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction . Such an offer can only be made by prospectus or other author
Slide 3: Who We Are
I/O Company with 4 First/Best in Class Small Molecules in the Clinic Who We Are Cash Runway for Current Programs Potentially Extended into 2024 Veteran Team from BMS, with 10 Oncology Approvals and Multiple Billion $ Exits Nine Phase 1b/2 Data Catalysts in Eight Tumor Types Over Next 18 - 24 Months
Slide 4: Proven Leadership with Oncology and Financing Expertise
Allan Shaw CFO Justin Fairchild VP Clin Dev Proven Leadership with Oncology and Financing Expertise Board of Directors Gregory Bailey, MD Rob Glassman, MD Linda M. Kozick Jim Mellon Mark Simon Ian Walters, MD CEO, Chairman Rob Kramer, PhD CSO Steve Innaimo VP PM & Operations Brian Wiley CBO Steven M
Slide 5: Our Formula for Success
Our Formula for Success De - Risked Research Innovative Structure Strong Academic & Industry Network Developing First/Best in class I/O agents Potential for Large Returns Right experiments at the right time Capital efficient model Big pharma insights Targeting ~70 - 80% of patients that do not respo
Slide 6: Our Strategic Approach for Success in Immuno-Oncology
Our Strategic Approach for Success in Immuno - Oncology 6 Implement strategies to avoid late - stage clinical failure Look for broad targets Only test agents with single agent activity Test non - overlapping MOA’s Do randomized studies early Enrich patient population when possible Create competitive
Slide 7: Advantageous Approach to Immuno-Oncology Therapeutics Development
Advantageous Approach to Immuno - Oncology Therapeutics Development Drug Class Adaptive Immune System Tumor Microenvironment Innate Immune System Direct Tumor Checkpoint iNKT agonists DC, B, & T - cells MDSC, M PMN NK In CD1d + cells Combine with approved PD - 1 Adenosine compounds DC & T - cells
Slide 8: Nine Near Term Phase 1b/2 Data Catalysts
Nine Near Term Phase 1b/2 Data Catalysts PLATFORM TECHNOLOGY ASSET INDICATION STAGE # of PTS PORT - 2 iNKT Agonists Liposomal Formulations IMM60 Melanoma + NSCLC Phase 1 18 ᬚ PORT - 2 iNKT Agonists Liposomal Formulations IMM60 Refractory Melanoma Phase 2 10 ᬛ PORT - 2 iNKT Agonists Liposomal Formula
Slide 9: iNKT agonists PORT-2, PORT-
iNKT agonists PORT - 2, PORT - 3 Activating the innate, adaptive immune system and correcting the TME
Slide 10: PORT-2 is a Rationally Designed Liposome Containing IMM60
PORT - 2 is a Rationally Designed Liposome Containing IMM60 Binds to TCR on iNKT Put in charged liposome to protect lipid chain and promote Type 1 cytokine release iNKT cell Hydrophilic head Hydrophobic tail • Taken up by APC • Present to CD1d • Re - cycle to surface Binds to CD1d on APC and other m
Slide 11: Portage's iNKT agonist (PORT-2) Stimulates Multiple Arms of the Immune System
iNKT cell Portage’s iNKT agonist (PORT - 2) Stimulates Multiple Arms of the Immune System Innate Immune System Tumor Microenvironment Adaptive Immune System 11
Slide 12: PORT-2 (IMM60) Demonstrates Superior Response Versus PD-1 Antibody
12 Source: Jukes et al Eur. J. Immunol. 2016. 00: 1 – 11 PORT - 2 (IMM60) Demonstrates Superior Response Versus PD - 1 Antibody IMM60 (0.5ng/mouse) PORT - 2 Vehicle + anti PD - 1 Vehicle untreated PORT - 2 shows better response rates vs anti - PD - 1 in melanoma animals B16 melanoma lung metastases
Slide 13: IMPORT-01: Dose Escalation with Best-in-Class Design for NSCLC and Melanoma
13 Source: https:// www.isrctn.com/ISRCTN80472712 IMPORT - 201: Dose Escalation with Best - in - Class Design for NSCLC and Melanoma PORT - 2 PORT - 2 + PD - 1 Phase 1 in refractory melanoma and NSCLC Phase 1/2 Trial Primary investigator Mark Middleton, Churchill Hospital, Oxford: 3 additional sites
Slide 14: ASCO 2022 Interim Data Confirms PORT-2 MOA and Shows Good Safety
14 ASCO 2022 ASCO 2022, Interim Data Confirms PORT - 2 MOA and Shows Good Safety Tumor type 2 Melanoma 3 NSCLC Age 64 (41,79) Median prior therapies 5(3,7) Prior PD - 1 100% Performance status 40% ECOG 0 60% ECOG 1 Baseline 3 months • MCP - 1 and IP - 10 showed increases in most subjects, no increas
Slide 15: IMPORT-201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma
15 Source: https:// www.isrctn.com/ISRCTN80472712 Multi - arm study with four Phase 2 readouts in 2023/2024 IMPORT - 201: Phase 2 Evaluates Front Line NSCLC and Refractory Melanoma PD - 1 q3wk iv infusions n=15 PD - 1 naïve patients PORT - 2 One dose @ MTD n=15 PORT - 2 + PD - 1 6 x iv infusions q3w
Slide 16: Adenosine Portfolio
Adenosine Portfolio Unique position to modulate Adenosine in 4 different ways PORT - 6 A2AR Inhibitor PORT - 7 A2BR Inhibitor PORT - 8 A2AR/A2BR Dual Inhibitor PORT - 9 Gut - restricted A2BR Inhibitor
Slide 17: Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment
17 Targeting Adenosine in Cancer Immunotherapy to Enhance T - Cell Function; Virgano, et al; Frontiers in Immunology 2019 modified slightly and used under CC BY 4.0 Leveraging A2A and A2B Alone or in Combo Allows for Customization of Treatment Macrophage Treg T cell NK Cell Endothelial Cell CAF MDSC
Slide 18: Fast Follower with Superior Profile Enables Best in Class Development
1. ASCO 2021 2. AACR 2021/2022 18 * Expression data from Labcorp A2A (TKI’s from iTeos, Corvus, Arcus, AZ, BMS, Merck, Schering Plough and more): • iTeos monotherapy activity demonstrated only at high doses and with BID administration (more durable blockade) 1 • 17% ORR at 80mg BID (RP2 dose) • Othe
Slide 19: PORT-6: Best-in-Class A2A - More Selective, More Potent, & More Durable
19 PORT - 6: Best - in - Class A2A - More Selective, More Potent, & More Durable 1 Data on File 2 AACR 2019 3 Cancer Immunology Research 2018 4 ASCO GU 2020, SITC 2018 Key Parameters PORT - 6 Portage 1 EOS - 850 iTeos 2 CPI - 444 Corvus 3 AB928 Arcus 4 Significance Potency (cAMP functional inhibitio
Slide 20: PORT-7: Highly Selective and Potent A2B Adenosine Receptor Antagonist
20 Data on File PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages • Activity in 4T1, CT26, and other disease models (Asthma, fibrosis, sickle cell) • IND approved for pro - drug Binding Affinity F
Slide 21: ADPORT-601: Adaptive Phase 1a/1b Study
21 ADPORT - 601 : Adaptive Phase 1a/1b Study Phase 1a Starting Dose (10 mg BID) (n=12 - 15) A2AR (PORT - 6) indications: A2BR (PORT - 7) indications: Colorectal Cancer, Non - small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer with high A2B expression Prostate Cancer, Non - small Cell Lung Ca
Slide 22: Strong U.S. and Global IP Positions on Platforms and Products
iNKT Agonists • Formulations with antigens, other I/O agents • Liposomes/particles 2031 - 2036 Patent Exclusivity Many Applications Pending Worldwide Strong U.S. and Global IP Positions on Platforms and Products Broad and deep intellectual property covering: >60 Issued Patents Adenosine Inhibitors •
Slide 23: Summary Financial Data
Summary Financial Data Cash Balance (06/30/22) ~$21.2 million Committed Purchase Lincoln Park Capital $30 million Debt $ - Shares Outstanding (08/31/22) 16,943,672 Insider Ownership 52% Public Float* 48% Options & RSUs Outstanding (08/31/22) 1,217,300 Warrants Outstanding (08/31/22) 33,888 Net Loss
Slide 24: Key Upcoming Clinical Development Milestones
Key Upcoming Clinical Development Milestones* 2022 2023 2024 Q4 Q1 Q2 Q3 Q4 1H 2H IMPORT - 201 P2 start IMPORT - 201 P1 presentation PORT - 5 IND submission IMPORT - 201 P2 ORR data ADPORT - 601 study activation ADPORT - 601 1b start IMPORT - 201 US IND/ EU CTA IMPORT - 201 ASCO IMPORT - 201 present
Slide 25: Novel, Clinical Stage I/O Portfolio with Small Molecule Focus
Novel, Clinical Stage I/O Portfolio with Small Molecule Focus • Manufacturing simplicity, low capital investment • Nine phase 1b/2 clinical data reads over next 2 years Engine for Efficient Drug Development & Commercialization • Expert scientific oversight • Lean structure with good cash runway Pref
Portage Biotech — Investor Presentation (September 2022) on 6ix